If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in ...
Teva Pharmaceutical (NYSE:TEVA) announced on Wednesday that the U.S. Food and Drug Administration (FDA) approved its migraine therapy Ajovy for children and adolescents, expanding its previous label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback